Drug Profile
Tesetaxel - Odonate Therapeutics
Alternative Names: DJ-927Latest Information Update: 11 Aug 2021
Price :
$50
*
At a glance
- Originator Daiichi Pharmaceutical
- Developer Genta (CEASED); Odonate Therapeutics
- Class Amines; Antineoplastics; Benzoates; Carbamates; Dioxolanes; Pyrimidines; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer; Brain metastases; Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours
Most Recent Events
- 11 Aug 2021 Genta withdraws a phase III trial in Gastric cancer (First-line therapy) prior to enrolment as the company is no longer functioning
- 30 Jul 2021 Odonate Therapeutics terminates a phase II CONTESSA 2 trial in Breast cancer (First-line therapy, Metastatic disease, Late-stage disease, Combination therapy) in USA, Australia, Canada, Spain, South Korea, Taiwan, due to sponsor's decision to discontinue the development of trial drug (NCT03858972)
- 30 Jul 2021 Odonate Therapeutics terminates a phase II CONTESSA TRIO trial for Breast cancer (Metastatic disease, First-line therapy, Monotherapy, Late-stage disease, In the elderly) in USA, Spain, South Korea, Poland, Germany, France and Singapore, due to sponsor's decision to discontinue the development of the trial drug (NCT03952325) (EudraCT2018-004715-41)